NCT03770052

Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie

A Double Blind, Randomized, Investigator Initiated Study on Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie (Lobeglitazone) in Patients With Type 2 Diabetes With Inadequate Control on Metformin and DPP-4 Inhibitor Therapy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 159 (actual)
• Sponsor: Pusan National University Hospital · Academic / Other
• Sex: All
• Age: 19 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie

Detailed description

This study is a double blind, randomized, investigator initiated study on glucose-lowering effects and Safety of Adding 0.25 or 0.5 mg Duvie (Lobeglitazone) in Patients With Type 2 Diabetes With Inadequate Control on Metformin and DPP-4 Inhibitor Therapy. The primary aim of the study is to compared changes of HbA1c between 0.25mg robeblitazone add-on group and 0.5mg robeglitazone add-on group.

Conditions

• Type 2 Diabetes Mellitus
• Inadequate Glucose Control

Interventions

Type	Name	Description
DRUG	duvie	take the intervention drug once daily according to the randomized groups

Timeline

• Start date: 2018-10-24
• Primary completion: 2021-08-19
• Completion: 2021-09-13
• First posted: 2018-12-10
• Last updated: 2022-01-20

Locations

1 site across 1 country: South Korea